Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Canopus BioPharma said that its drug candidate StatC has shown superior efficacy to Roche's Tamiflu in mouse models with avian flu, Spanish flu and Hong Kong flu strains.
Subscribe to our email newsletter
In the studies, 30% of StatC-treated lung samples had H5N1 virus detected in comparison to 50% of Tamiflu treated samples, according to the company. Histopathology which measures lung damage due to influenza infection demonstrated in these studies that mice treated with StatC had statistically significant reduction in lung damage as compared to the group treated with Tamiflu.
Patrick Prendergast, CEO of Canopus BioPharma, said: “The StatC formulation has proved superior to Tamiflu in mouse studies carried out in China by Prof. Jiahai Lu and the research results are being prepared for publication. We believe our results will be viewed as an important scientific breakthrough in the global fight to prevent and treat multiple strains of influenza.”
Canopus BioPharma’s strategy for developing its StatC drug includes continued animal testing in partnership with its extensive network of European- and Chinese-based biotechnology research laboratories. In addition, a human influenza challenge study will be conducted to compare StatC as a preventative intervention for influenza against other currently available antivirals.